Harrow Health, Inc. is an ophthalmology-focused healthcare company. The company is headquartered in San Diego, California.
| Revenue (TTM) | $275.59M |
| Gross Profit (TTM) | $201.96M |
| EBITDA | $17.71M |
| Operating Margin | -15.60% |
| Return on Equity | -116.10% |
| Return on Assets | -0.45% |
| Revenue/Share (TTM) | $7.40 |
| Book Value | $0.41 |
| Price-to-Book | 64.22 |
| Price-to-Sales (TTM) | 3.66 |
| EV/Revenue | 4.329 |
| EV/EBITDA | 104.85 |
| Quarterly Earnings Growth (YoY) | -10.30% |
| Quarterly Revenue Growth (YoY) | 10.90% |
| Shares Outstanding | $37.49M |
| Float | $28.93M |
| % Insiders | 15.38% |
| % Institutions | 59.81% |
Volatility is currently expanding
Harrow (HROW) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NASHVILLE, Tenn., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the launch of HarrowRx, a prescribing and access pharmacy platform that enables eyecare professionals to access Harrow's entire portfolio directly within the electronic medical record (EMR) systems they already use.
Harrow trades at a 52-week low due to management miscommunication and short-term revenue volatility, but its fundamentals remain robust. Vevye and Iheezo, Harrow's flagship drugs, both address large, underpenetrated markets and are positioned for significant growth as coverage expands and pricing stabilizes. Temporary headwinds, including inventory dynamics and coverage transitions, have obscured accelerating prescription trends and pricing tailwinds expected to materialize in H2 and beyond.
Investors need to pay close attention to HROW stock based on the movements in the options market lately.
First and Only FDA-Approved Nasal Spray for Dry Eye Disease Adds a Differentiated, Drop-Free Treatment Option to Harrow's Growing Ocular Surface Franchise First and Only FDA-Approved Nasal Spray for Dry Eye Disease Adds a Differentiated, Drop-Free Treatment Option to Harrow's Growing Ocular Surface Franchise
NASHVILLE, Tenn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will participate in the following three investor conferences in September in New York, NY: 2026 Cantor Global Healthcare Conference Format: Fireside chat + 1x1 investor meetings Date/Time: Wednesday, September 9, 2026, at 1:35 p.m.
Patients reported approximately 58% less discomfort overall in the IHEEZO-treated eye, with the largest absolute differences in the immediate post-injection period, when discomfort is highest Patients reported approximately 58% less discomfort overall in the IHEEZO-treated eye, with the largest absolute differences in the immediate post-injection period, when discomfort is highest
Harrow, Inc. (HROW) Q2 2026 Earnings Call Transcript
Harrow NASDAQ: HROW reported second-quarter revenue of $70.7 million, up 11% from a year earlier and about 60% sequentially, as the ophthalmic pharmaceutical company said it entered the second half of 2026 with stronger demand across several products, improved pricing and expanded commercial infrastructure.
Harrow (HROW) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to earnings of $0.24 per share a year ago.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on HROW and any ticker you trade — then tracks every position and per-strategy win rate.
